Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04WMR
|
|||
| Former ID |
DNC001423
|
|||
| Drug Name |
Tepoxalin
|
|||
| Synonyms |
TEPOXALIN; 103475-41-8; Orf-20485; ORF 20485; Tepoxaline; Tepoxalina; Tepoxalinum [Latin]; Tepoxaline [French]; Tepoxalina [Spanish]; RWJ 20485; Tepoxalin [USAN:INN]; 5-(4-Chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; UNII-TZ4OX61974; C20H20ClN3O3; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-; CHEMBL316040; CHEBI:76277; TZ4OX61974; 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid; RWJ-20485; SIL-4R
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H20ClN3O3
|
|||
| Canonical SMILES |
CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O
|
|||
| InChI |
1S/C20H20ClN3O3/c1-23(26)20(25)12-7-16-13-19(14-3-5-15(21)6-4-14)24(22-16)17-8-10-18(27-2)11-9-17/h3-6,8-11,13,26H,7,12H2,1-2H3
|
|||
| InChIKey |
XYKWNRUXCOIMFZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 103475-41-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
611043, 8186496, 12014232, 14756201, 43117257, 47207733, 50029520, 51014614, 57313968, 99222754, 103289646, 103915673, 104319001, 117469332, 124489036, 125822839, 126659291, 126666634, 127318325, 127318326, 127318327, 127318328, 129759067, 134340530, 134340609, 135017939, 136946591, 137237556, 142054088, 162201641, 164234071, 164765260, 170466265, 170474353, 172919648, 175611027, 179149497, 196108272, 198976094, 223653354, 223758677, 226455142, 242060045, 252216397
|
|||
| ChEBI ID |
CHEBI:76277
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids. 1997 Jun;56(6):417-23. | |||
| REF 2 | Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48. | |||
| REF 3 | Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.